Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders

Prakash S. Masand, Xiaohong Wang, Sanjay Gupta, Thomas L. Schwartz, Subhdeep Virk, Ahmad Hameed

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To compare risperidone and olanzapine for efficacy, tolerability, need for concomitant mood stabilizers, and cost of treatment in bipolar and schizoaffective disorders. Method: We conducted a retrospective chart review of 36 consecutive outpatients with DSM-IV bipolar or schizoaffective disorder seen in 3 settings who received risperidone or olanzapine for at least 1 month between May and August 1997. Results: The mean ±SD doses were.3.7 ±3.5 mg/day of risperidone and 12.0 ±5.4 mg/day of olanzapine, Between-treatment differences in patient characteristics, psychiatric history, Clinical Global Impressions scale ratings, and duration of treatment were not significant. Similar proportions of patients in the 2 groups reported side effects, including extrapyramidal symptoms, akathisia. tardive dyskinesia, and precipitation of mania by the respective drug. Patients in the olanzapine group received a significantly higher dose of concomitant lithium than those receiving risperidone (mean daily lithium doses: risperidone group, 750 ±150 mg; olanzapine group, 1211 ±186 mg; p =.006). The total daily acquisition cost per patient was SI 1.84 for olanzapine versus $5.81 for risperidone. Conclusion: Olanzapine and risperidone were equally efficacious and safe in the treatment of patients with bipolar or schizoaffective disorder, but treatment costs and dose of concomitant lithium were lower in risperidone-treated patients.

Original languageEnglish (US)
Pages (from-to)70-73
Number of pages4
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

olanzapine
Risperidone
Bipolar Disorder
Psychotic Disorders
Lithium
Health Care Costs
Psychomotor Agitation
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Masand, Prakash S. ; Wang, Xiaohong ; Gupta, Sanjay ; Schwartz, Thomas L. ; Virk, Subhdeep ; Hameed, Ahmad. / Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2002 ; Vol. 4, No. 2. pp. 70-73.
@article{6f7cd7acee2846718f16315837b1d57b,
title = "Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders",
abstract = "Objective: To compare risperidone and olanzapine for efficacy, tolerability, need for concomitant mood stabilizers, and cost of treatment in bipolar and schizoaffective disorders. Method: We conducted a retrospective chart review of 36 consecutive outpatients with DSM-IV bipolar or schizoaffective disorder seen in 3 settings who received risperidone or olanzapine for at least 1 month between May and August 1997. Results: The mean ±SD doses were.3.7 ±3.5 mg/day of risperidone and 12.0 ±5.4 mg/day of olanzapine, Between-treatment differences in patient characteristics, psychiatric history, Clinical Global Impressions scale ratings, and duration of treatment were not significant. Similar proportions of patients in the 2 groups reported side effects, including extrapyramidal symptoms, akathisia. tardive dyskinesia, and precipitation of mania by the respective drug. Patients in the olanzapine group received a significantly higher dose of concomitant lithium than those receiving risperidone (mean daily lithium doses: risperidone group, 750 ±150 mg; olanzapine group, 1211 ±186 mg; p =.006). The total daily acquisition cost per patient was SI 1.84 for olanzapine versus $5.81 for risperidone. Conclusion: Olanzapine and risperidone were equally efficacious and safe in the treatment of patients with bipolar or schizoaffective disorder, but treatment costs and dose of concomitant lithium were lower in risperidone-treated patients.",
author = "Masand, {Prakash S.} and Xiaohong Wang and Sanjay Gupta and Schwartz, {Thomas L.} and Subhdeep Virk and Ahmad Hameed",
year = "2002",
month = "1",
day = "1",
doi = "10.4088/PCC.v04n0205",
language = "English (US)",
volume = "4",
pages = "70--73",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. / Masand, Prakash S.; Wang, Xiaohong; Gupta, Sanjay; Schwartz, Thomas L.; Virk, Subhdeep; Hameed, Ahmad.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 4, No. 2, 01.01.2002, p. 70-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders

AU - Masand, Prakash S.

AU - Wang, Xiaohong

AU - Gupta, Sanjay

AU - Schwartz, Thomas L.

AU - Virk, Subhdeep

AU - Hameed, Ahmad

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: To compare risperidone and olanzapine for efficacy, tolerability, need for concomitant mood stabilizers, and cost of treatment in bipolar and schizoaffective disorders. Method: We conducted a retrospective chart review of 36 consecutive outpatients with DSM-IV bipolar or schizoaffective disorder seen in 3 settings who received risperidone or olanzapine for at least 1 month between May and August 1997. Results: The mean ±SD doses were.3.7 ±3.5 mg/day of risperidone and 12.0 ±5.4 mg/day of olanzapine, Between-treatment differences in patient characteristics, psychiatric history, Clinical Global Impressions scale ratings, and duration of treatment were not significant. Similar proportions of patients in the 2 groups reported side effects, including extrapyramidal symptoms, akathisia. tardive dyskinesia, and precipitation of mania by the respective drug. Patients in the olanzapine group received a significantly higher dose of concomitant lithium than those receiving risperidone (mean daily lithium doses: risperidone group, 750 ±150 mg; olanzapine group, 1211 ±186 mg; p =.006). The total daily acquisition cost per patient was SI 1.84 for olanzapine versus $5.81 for risperidone. Conclusion: Olanzapine and risperidone were equally efficacious and safe in the treatment of patients with bipolar or schizoaffective disorder, but treatment costs and dose of concomitant lithium were lower in risperidone-treated patients.

AB - Objective: To compare risperidone and olanzapine for efficacy, tolerability, need for concomitant mood stabilizers, and cost of treatment in bipolar and schizoaffective disorders. Method: We conducted a retrospective chart review of 36 consecutive outpatients with DSM-IV bipolar or schizoaffective disorder seen in 3 settings who received risperidone or olanzapine for at least 1 month between May and August 1997. Results: The mean ±SD doses were.3.7 ±3.5 mg/day of risperidone and 12.0 ±5.4 mg/day of olanzapine, Between-treatment differences in patient characteristics, psychiatric history, Clinical Global Impressions scale ratings, and duration of treatment were not significant. Similar proportions of patients in the 2 groups reported side effects, including extrapyramidal symptoms, akathisia. tardive dyskinesia, and precipitation of mania by the respective drug. Patients in the olanzapine group received a significantly higher dose of concomitant lithium than those receiving risperidone (mean daily lithium doses: risperidone group, 750 ±150 mg; olanzapine group, 1211 ±186 mg; p =.006). The total daily acquisition cost per patient was SI 1.84 for olanzapine versus $5.81 for risperidone. Conclusion: Olanzapine and risperidone were equally efficacious and safe in the treatment of patients with bipolar or schizoaffective disorder, but treatment costs and dose of concomitant lithium were lower in risperidone-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=2542437816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542437816&partnerID=8YFLogxK

U2 - 10.4088/PCC.v04n0205

DO - 10.4088/PCC.v04n0205

M3 - Article

AN - SCOPUS:2542437816

VL - 4

SP - 70

EP - 73

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 2

ER -